DaVita Shares Drop Despite Strong Q2 Earnings and Rising Margins

Strong Earnings Performance from DaVita Inc.

DaVita Inc. (DVA) delivered impressive results in the second quarter of 2025, with adjusted earnings per share (EPS) reaching $2.95, a 13.9% increase compared to the same period last year. This figure exceeded the Zacks Consensus Estimate by 9.3%, showcasing strong financial performance. On a GAAP basis, EPS for the quarter was $2.58, reflecting a 3.2% year-over-year growth.

Revenue Growth and Key Drivers

The company reported total revenues of $3.38 billion for the second quarter, an increase of 6.1% compared to the previous year. This outperformed the Zacks Consensus Estimate by 1.3%. The revenue per treatment for the quarter stood at $404.6 million, rising 3.7% year over year and 1.1% sequentially. According to management, this growth was primarily driven by seasonal improvements, including patients meeting their co-insurance and deductibles. However, this was partially offset by a decline in the volume of phosphate binders.

Despite these positive trends, shares of DaVita experienced a sharp drop of nearly 10.1% during the last trading session, raising concerns among investors.

Segment Performance

DaVita generates revenue through two main segments: Dialysis patient service revenues and Other revenues. The dialysis patient service revenues reached $3.21 billion, up 4.8% year over year. Meanwhile, Other revenues climbed to $172.7 million, marking a 37.4% increase from the previous year’s quarter.

As of June 30, 2025, DaVita provided dialysis services to approximately 283,100 patients across 3,175 outpatient dialysis centers. Of these, 2,662 were located in the U.S., while 513 were spread across 13 other countries. During the second quarter, the company opened three new centers in the U.S., closed two, and acquired one. Internationally, it opened six and closed five centers.

In its Integrated Kidney Care business, DaVita had around 64,400 patients in risk-based integrated care arrangements, representing $5.3 billion in annualized medical spend. An additional 9,300 patients were part of other integrated care arrangements.

Financial Highlights

Gross profit for the quarter rose 7% year over year to $1.12 billion, with gross margin expanding 31 basis points (bps) to 33.1%. General and administrative expenses increased by 12.2% year over year to $412.8 million. Adjusted operating profit totaled $705.2 million, a 4.2% increase from the prior-year quarter. However, the adjusted operating margin contracted 36 bps to 20.9%.

DaVita ended the second quarter with cash and cash equivalents and short-term investments of $739.4 million, up from $511.9 million at the end of the first quarter. Total debt, including the current portion, was $10.26 billion as of June 30, 2025, compared to $9.74 billion at the end of the first quarter. Net cash provided by operating activities for the quarter was $504.2 million, down slightly from $664 million a year ago.

During the three months ended June 30, 2025, DVA repurchased 3.1 million shares for $446 million.

Guidance and Outlook

DaVita has reaffirmed its adjusted EPS guidance for 2025, projecting a range of $10.20 to $11.30. The Zacks Consensus Estimate currently stands at $10.76.

Analyst Take on DaVita

DaVita’s second-quarter results were largely positive, with strong top- and bottom-line growth and improved revenue per treatment. The sequential increase in U.S. dialysis treatments and solid performance from both revenue streams were encouraging. Additionally, the expansion of dialysis centers in the U.S. and overseas signaled promising growth.

However, the year-over-year decline in normalized non-acquired treatment was a concern. The contraction in adjusted operating margin also raised questions about the company’s long-term profitability.

Zacks Rank and Competitors

DaVita currently holds a Zacks Rank of #3 (Hold). In the broader medical sector, several stocks with higher Zacks Ranks have recently reported strong quarterly results:

• GE HealthCare Technologies Inc. (GEHC): Holding a Zacks Rank of #1 (Strong Buy), GEHC reported second-quarter adjusted EPS of $1.06, surpassing estimates by 16.5%. Its long-term estimated growth rate is 5.8%.
• West Pharmaceutical Services, Inc. (WST): With a Zacks Rank of #1, WST posted adjusted EPS of $1.84, beating estimates by 21.9%. It has a long-term estimated growth rate of 8.4%.
• Boston Scientific Corporation (BSX): Carrying a Zacks Rank of #2 (Buy), BSX reported adjusted EPS of 75 cents, exceeding estimates by 4.2%. Its long-term estimated growth rate is 14%.

These companies demonstrate strong performance and offer potential investment opportunities in the medical sector.